ACTUATE THERAPEUTICS INC (ACTU:NASDAQ)

$1.88 -0.11 (-5.5276%)

watchlist-icon
search-icon
Profile Icon

Most Recent Average Sentiment Analysis Score (0 to 100): 82

negative-sentiment
Negative [0, 35)
neutral-sentiment
Neutral [35, 65]
positive-sentiment
Positive (65, 100]
Visualize Sentiment Trendline

Analysed ACTUATE THERAPEUTICS INC (ACTU:NASDAQ) News Sources

Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers

21-01-2026

yahoo.com

Actuate Therapeutics, Inc.'s (NASDAQ:ACTU) market cap dropped US$13m last week; Private equity firms bore the brunt

04-02-2026

yahoo.com

Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

24-02-2026

yahoo.com

Actuate Therapeutics to Present at The Citizens Life Sciences Conference

04-03-2026

yahoo.com

Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors

09-03-2026

yahoo.com

Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers

24-03-2026

yahoo.com

Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

14-04-2026

yahoo.com

Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors

06-05-2026

yahoo.com

Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program

11-05-2026

yahoo.com

Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer

01-06-2026

yahoo.com

ACTUATE THERAPEUTICS INC (ACTU:NASDAQ) Sentiment Trend

0 25 50 75 100 85 90 87 86 86 91 74 75 83 67 21-01-2026 04-02-2026 24-02-2026 04-03-2026 09-03-2026 24-03-2026 14-04-2026 06-05-2026 11-05-2026 01-06-2026 #1 #2 #3 #4 #5 #6 #7 #8 #9 #10 Negative < 35 Neutral 35–65 Positive > 65 View FAQ

ACTUATE THERAPEUTICS INC (ACTU:NASDAQ) FAQs

toggle

What is the current price of ACTUATE THERAPEUTICS INC (ACTU:NASDAQ)?

The current price of ACTUATE THERAPEUTICS INC (ACTU:NASDAQ) is $1.88.


toggle

ACTUATE THERAPEUTICS INC (ACTU:NASDAQ) absolute price change since previous trading day?

The absolute price change of ACTUATE THERAPEUTICS INC (ACTU:NASDAQ) since the previous trading day is $-0.11.


toggle

ACTUATE THERAPEUTICS INC (ACTU:NASDAQ) percentage price change since previous trading day?

The percentage price change of ACTUATE THERAPEUTICS INC (ACTU:NASDAQ) since the previous trading day is -5.5276%.


toggle

What is the most recent average sentiment score for ACTUATE THERAPEUTICS INC (ACTU:NASDAQ)?

The most recent average sentiment score for ACTUATE THERAPEUTICS INC (ACTU:NASDAQ) is 82 out of 100.


toggle

What is the most recent average sentiment for ACTUATE THERAPEUTICS INC (ACTU:NASDAQ)?

The most recent sentiment for ACTUATE THERAPEUTICS INC (ACTU:NASDAQ) is .


SEC-8K** Filing Available For ACTUATE THERAPEUTICS INC (ACTU:NASDAQ)

** material developments that could impact a company's financial condition or stock price.

Author: MattELab

X Icon

GitHub Icon

MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.